©2022 Stanford Medicine
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Trial ID: NCT00833417
This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients received vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.
A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma
- Men and women ≥ 18 years of age.
- For patients with metastatic basal cell carcinoma (BCC), histological confirmation of
distant BCC metastasis (eg, lung, liver, lymph nodes, or bone), with metastatic
disease that is Response Evaluation Criteria in Solid Tumors (RECIST) measurable using
computed tomography (CT) or magnetic resonance imaging (MRI).
- For patients with locally advanced BCC, histologically confirmed disease that is
considered to be inoperable.
- For patients with locally advanced BCC, radiotherapy must have been previously
administered for their locally advanced BCC, unless radiotherapy is contraindicated or
inappropriate. For patients whose locally advanced BCC has been irradiated, disease
must have progressed after radiation.
- For women of childbearing potential, agreement to the use of two acceptable methods of
contraception, including one barrier method, during the study and for 12 months after
discontinuation of vismodegib (GDC-0449).
- For men with female partners of childbearing potential, agreement to use a latex
condom, and to advise their female partner to use an additional method of
contraception during the study and for 3 months after discontinuation of vismodegib.
- Prior treatment with vismodegib or other Hedgehog pathway inhibitors.
- Pregnancy or lactation.
- Life expectancy of < 12 weeks.
- Patients with superficial multifocal BCC who may be considered unresectable due to
breadth of involvement.
- Concurrent non-protocol-specified anti-tumor therapy (eg, chemotherapy, other targeted
therapy, radiation therapy, or photodynamic therapy).
- Recent, current, or planned participation in an experimental drug study.
- History of other malignancies within 3 years of the first day of treatment with
vismodegib in this study (Day 1), except for tumors with a negligible risk for
metastasis or death, such as adequately treated squamous-cell carcinoma of the skin,
ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix.
- Uncontrolled medical illnesses such as infection requiring treatment with intravenous
drug: Vismodegib 150 mg
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office